

**PRESS RELEASE****STALLERGENES INVESTOR DAY**

**Antony, France, 19 February 2013** – Stallergenes (Euronext Paris CAC Small) is holding today its investor day at its headquarters in Antony, France. It will be live webcasted on its website and available at <http://www.media-server.com/m/p/66b4gn2y>. It will remain available after the event.

On this occasion, Stallergenes will elaborate on the Group's strategic vision aimed at establishing its worldwide leadership in allergen immunotherapy. In this regard, a particular focus will be devoted to the US immunotherapy market.

The Group will also comment on its development potential on the allergic rhinitis market, and will emphasize its willingness to expand in the field of allergic asthma. Stallergenes will notably present the first steps of its development plan for House Dust Mite-associated Allergic Asthma.

Presentations will be followed by a visit of the Group's production site and global Research & Development center.

**ABOUT STALLERGENES**

Stallergenes is an international biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes around 20% of its annual gross sales to Research & Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2012, the company generated sales of € 243 million, and more than 500,000 patients were treated with Stallergenes products.

Euronext Paris (Compartment B)  
CAC small  
ISIN: FR0000065674  
Reuters: GEN.PA  
Bloomberg: GEN.FP



Additional financial information is available at <http://finance.stallergenes.com>

**Contacts:**

Roberto Gradnik, Chief Executive Officer  
Tel. +33 1 55 59 20 04

**Investor and analyst relations**

Christian Thiry  
Chief Financial Officer  
Tel. +33 1 55 59 20 95  
e-mail: investorrelations@stallergenes.com

**Press Relations**

Lise Lemonnier,  
Senior Communication & Public Affairs Director  
Tel. + 33 1 55 59 20 96  
e-mail: llemonnier@stallergenes.com

**Investor and press relations agency:**

F T I Consulting – Analyst and investor contact  
Stéphanie Bia  
Tel. +33 1 47 03 68 16  
stephanie.bia @fticonsulting.com

FTI Consulting – Press contact  
Emmanuelle Flobert  
Tel. +33 1 47 03 68 56  
emmanuelle.flobert@fticonsulting.com